Business context and reporting period
Entity mismatch: The supplied filing is Diffusion Pharmaceuticals Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2022, not a filing identified as Cervomed Inc. Diffusion is a clinical-stage biopharmaceutical company developing trans sodium crocетinate (TSC) to improve oxygen delivery to hypoxic tissue. Its lead program includes development for glioblastoma (GBM). Share and per-share figures reflect a 1-for-50 reverse stock split effective April 18, 2022.
Financial results and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $2.11 million | $1.97 million | $4.53 million | $4.89 million |
| General and administrative | $2.14 million | $1.84 million | $4.27 million | $3.58 million |
| Net loss | $4.19 million | $3.78 million | $8.72 million | $8.42 million |
| Net loss per share | $2.06 | $1.85 | $4.28 | $4.54 |
| Cash used in operating activities | Not separately presented by quarter | $8.74 million | $8.50 million |
At June 30, 2022, cash and cash equivalents were $5.97 million and available-for-sale marketable securities were $22.57 million, totaling $28.54 million. Working capital was $26.67 million; current liabilities were $2.52 million, and the company reported no debt or committed credit facility. Total assets were $29.18 million and stockholders’ equity was $26.67 million. Accumulated deficit was $138.72 million. Profitability and operating margins are not meaningful given the absence of product revenue and continuing losses.
Material changes versus the prior comparable period
- Q2 net loss increased by about $0.41 million year over year. R&D rose by $0.14 million and G&A by $0.30 million; management attributed expense movements primarily to clinical-trial and manufacturing timing, additional headcount, and professional fees associated with the reverse split.
- For the first half, net loss increased by about $0.30 million. R&D declined by $0.35 million, while G&A increased by $0.69 million; depreciation was zero versus $0.05 million in the prior-year period.
- Cash and cash equivalents fell from $37.31 million at year-end 2021 to $5.97 million at June 30, 2022, principally because funds were transferred into marketable securities. The company held no marketable securities at December 31, 2021; June 30 holdings had $22.57 million fair value and $0.09 million of unrealized losses, attributed primarily to interest-rate changes.
- First-half financing provided only $5,000, compared with $33.30 million in the prior-year period from common-stock sales and warrant exercises.
Outlook, management commentary, risks, and unusual items
- Management expected June 30 cash, cash equivalents, and marketable securities to fund operating expenses and capital needs into the first quarter of 2024, excluding business-development activities. The company anticipates substantial future losses and says additional financing will be required to complete development.
- In July 2022, after the quarter-end, the company entered into an at-the-market agreement allowing up to $20 million of common-stock sales, subject to applicable offering limits. It reported no sales under the agreement as of the filing date; any sales could dilute existing holders.
- Management reported positive changes in pH and lactate at the highest dose in the 30-person Altitude Trial. These are exploratory findings in healthy volunteers, not evidence of clinical benefit in patients.
- On July 26, 2022, the company said it had aligned with the FDA on the design of Study 200-208, an open-label Phase 2 dose-escalation study of TSC with standard GBM treatment. It expected to begin the study by year-end 2022 and dose the first patient in Q1 2023, subject to business-development outcomes. The design includes higher and more frequent dosing than prior GBM trials and PET imaging to assess tumor hypoxia.
- On August 9, 2022, after the reporting period, the company decided to stop recruitment and wind down the ILD-DLCO trial, citing enrollment challenges during the COVID-19 pandemic and a desire to focus resources on the GBM study and business development.
- A former executive’s lawsuit is pending, with trial set for May 24, 2023. The company considers the claims without merit but cannot estimate a possible loss; an adverse resolution could materially affect financial position, results, and cash flows.
- Funding is not assured. The company warns that inability to raise capital could require delaying, reducing, or ending programs, entering collaborations on less favorable terms, or ceasing operations. It also cited clinical, regulatory, manufacturing, enrollment, intellectual-property, third-party, and Nasdaq-listing risks.
Important facts for investors to verify
- Confirm the filing issuer: the document is for Diffusion Pharmaceuticals Inc., not Cervomed Inc.
- Track cash burn, marketable-security maturities, and whether the stated runway into Q1 2024 remains achievable.
- Check whether the company uses the $20 million ATM facility and the resulting dilution.
- Verify Study 200-208 startup, enrollment, safety, and PET-imaging milestones; these were forward-looking plans, not completed results.
- Assess the implications of ending the ILD-DLCO trial and the uncertain outcome and potential exposure from the pending lawsuit.